医学
肾细胞癌
肾切除术
彭布罗利珠单抗
无容量
磁共振成像
肾癌
放射科
佐剂
肿瘤科
免疫疗法
内科学
肾透明细胞癌
亚型
肾
黑色素瘤
癌
病理
烧蚀
计算机断层摄影术
辅助放疗
放射治疗
医学影像学
清除单元格
辅助治疗
作者
Akeem R. Lewis,Timothy D. Lyon,Sounak Gupta,Yousef Zakharia,Bradley C. Leibovich,Brian Addis Costello
出处
期刊:
[BMJ]
日期:2026-10-26
卷期号:395: e100785-e100785
标识
DOI:10.1136/bmj-2026-100785
摘要
Renal cell carcinoma (RCC) is the most common form of kidney cancer, with 435 000 patients newly diagnosed worldwide each year. In addition to morphology and histology, molecular subtyping has advanced the diagnostic classification of RCC. Contemporary diagnosis relies on cross sectional imaging in the form of computed tomography or magnetic resonance imaging and selective biopsy. For localised disease, nephrectomy remains the standard of care, with partial nephrectomy being an option for smaller tumours. Ablation or stereotactic radiation is appropriate for selected patients. Adjuvant pembrolizumab provides improved disease-free and overall survival in high risk clear cell RCC. In metastatic disease, the introduction of immune checkpoint inhibitor based combinations has extended overall survival, providing a durable response in some patients. Despite these advances, primary and secondary resistance, along with the lack of predictive and prognostic biomarkers, remain a challenge.
科研通智能强力驱动
Strongly Powered by AbleSci AI